Clinical Trials Logo

Filter by:
NCT ID: NCT03877224 Not yet recruiting - Clinical trials for Heart Failure With Preserved Ejection Fraction (HFpEF)

DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction

Start date: April 5, 2019
Phase: Phase 3
Study type: Interventional

International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Preserved Ejection Fraction (HFpEF)

NCT ID: NCT03876795 Recruiting - Clinical trials for Osteoarthritis, Knee

Evaluation of Effectiveness of Combined Intra-articular and Intra-osseus Injection VS a Single Intra-articular Injection of Bone Marrow Concentrate

INTERFACE
Start date: May 9, 2018
Phase: Phase 3
Study type: Interventional

Osteoarthritis (OA) is one of the most common diseases resulting in large burdens on society. Among the emerging treatments, Bone Marrow Concentrate (BMC) intra-articular injections are a promising regenerative approach. However, they offer only a temporary benefit since they target synovial and chondral tissues but fail to address the osteochondral interface, which plays a key role in the onset and progression of joint degeneration. This project will investigate the efficacy of combined BMC injections, targeting both intra-articular tissues and subchondral bone, to treat OA in a Randomized Controlled Trial (RCT).

NCT ID: NCT03875976 Recruiting - Hip Osteoarthritis Clinical Trials

Total Hip Arthroplasty: Fast Track Protocol is the Future?

FastTrack-H
Start date: March 1, 2018
Phase: N/A
Study type: Interventional

Fast-track total hip arthroplasty (THA) is a well-established concept including optimized logistics and evidence-based treatment, focusing on minimizing surgical stress and improved post-operative recovery. The aim of this protocol is to compare the standard care and fast track total hip arthroplasties in terms of functional and subjective outcomes, hospital staying, number of transfusions and analgesic consumption.

NCT ID: NCT03875742 Enrolling by invitation - Anesthesia Clinical Trials

Interfascial Blocks Executed by Novice Operators in a Simulator Model: a Comparison of Two Types of Needles

Start date: April 1, 2019
Phase: N/A
Study type: Interventional

This study will compare two different needles for interfascial blocks. All participants will execute the block on simulator with both needles. The participants will be randomized in two groups to choose the starting needle.

NCT ID: NCT03875495 Recruiting - Multiple Myeloma Clinical Trials

A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM)

Start date: March 6, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a non-randomized, open label, phase I/II, dose-escalation study, involving a single injection of Temferon, an investigational advanced therapy consisting of autologous CD34+-enriched hematopoietic stem and progenitor cells exposed to transduction with a lentiviral vector driving myeloid-specific interferon-ɑ2 expression, which will be administered to up to 9 patients affected by multiple myeloma in early relapse after intensive front line treatment.

NCT ID: NCT03875417 Completed - Quality of Life Clinical Trials

Multidisciplinary Management of HCC in Elderly Patients

Start date: January 1, 2018
Phase:
Study type: Observational

Aim of this study is to evaluate whether treating HCC recurrences in resected elderly patients is advantageous or not.

NCT ID: NCT03874312 Recruiting - Clinical trials for Advanced Heart Failure

Ultrasound-assessed Internal Jugular Vein Distensibility in Advanced Chronic Heart Failure (US-IJVD in CHF)

US-IJVD-CHF
Start date: October 18, 2017
Phase:
Study type: Observational

Prospective validation of the ultrasound-assessed internal jugular vein distensibility (JVD) ratio to identify patients with systolic chronic heart failure and right atrial pressure (RAP) of 7 or less mmHg measured by the right heart catheterization. In a calibration cohort, a threshold ratio will be identified, above which the RAP is normal with the highest accuracy. This diagnostic tool with a defined threshold of the JVD ratio will be assessed in a second prospective validation cohort.

NCT ID: NCT03873948 Completed - Metabolic Disorder Clinical Trials

Evaluation of Arginine in Periodontal and Cardiovascular Disease

Start date: January 6, 2014
Phase:
Study type: Observational

Asymmetric dimethylarginine (ADMA) plays a key role in endothelial function and may be a link for the known interaction of periodontitis and coronary heart disease (CHD). The investigators compared the impact of gingival health, periodontitis (CP), CHD or of both diseases (CP+CHD) on saliva and serum ADMA levels.

NCT ID: NCT03873935 Completed - Clinical trials for Vitamin D Deficiency

Vitamin D in Periodontal and Cardiovascular Disease Progression

Start date: January 2, 2015
Phase:
Study type: Observational

Vitamin D has been considered to possess anti-inflammatory and antimicrobial activity which may be a link for the known interaction of periodontitis (CP) and coronary heart disease (CHD). This study investigated the association between serum vitamin D levels and periodontitis in patients with CP and with CHD. Furthermore, the objective was to determine if periodontitis and CHD had an impact on serum vitamin D levels.

NCT ID: NCT03873064 Recruiting - Quality of Life Clinical Trials

Body Mass Index (BMI) and Quality of Life (QoL) in Cancer Patients

BMI-QoL
Start date: January 15, 2019
Phase:
Study type: Observational

BMI is a simple and widely recorded variable that may capture obesity or cachexia in cancer patients. How BMI is associated to health-related quality of life (HR-QoL) in such patients is poorly investigated. High BMI may be associated to obesity, an increased burden of comorbidity, reduced physical activity and, in some settings, to more aggressive oncological disease. On the other hand, low BMI may reflect enhanced weight loss, cachectic syndrome, higher tumor burden and adverse prognostic features which all deteriorate quality of life. The aim of the present study is to evaluate the association of BMI and HR-QoL as measured by the EORTC-QLQ-C30 questionnaire in several cancer settings (such as localized vs metastatic or distinct primary tumors).